Dual antiplatelet therapy and low-molecular-weight heparin significantly reduced early neurological deterioration compared to aspirin alone (4.12% and 3.11% vs 14.81%, p<0.001).
RCT (n=1,467)
Open-label
Computer-derived random sequences with sealed envelopes
Yes
Does dual antiplatelet therapy or low-molecular-weight heparin reduce early neurological deterioration compared to aspirin alone in patients with acute ischemic stroke?
In patients with acute ischemic stroke, dual antiplatelet therapy or low-molecular-weight heparin significantly reduced the incidence of early neurological deterioration and early recurrent ischemic stroke compared to aspirin alone, without increasing bleeding risk.
Absolute Event Rate: 4.12% vs 14.81%
p-value: p=<0.001
Background and PurposezzDual antiplatelet therapy (DAT) with clopidogrel and aspirin has been shown to confer greater protection against early neurological deterioration (END) and early recurrent ischemic stroke (ERIS) than aspirin alone in patients who have experienced an acute ischemic stroke. However, few studies have compared the effects of anticoagulation therapy with low-molecular-weight heparin (LMWH), DAT, and aspirin.
Yi et al. (Thu,) conducted a rct in Acute ischemic stroke (n=1,467). Dual antiplatelet therapy (DAT) or Low-molecular-weight heparin (LMWH) vs. Aspirin alone (200 mg daily) was evaluated on Incidence of early neurological deterioration (END) within 10 days after admission (p=<0.001). Dual antiplatelet therapy and low-molecular-weight heparin significantly reduced early neurological deterioration compared to aspirin alone (4.12% and 3.11% vs 14.81%, p<0.001).